Janet M Shipley

List of Publications by Year
in descending order

150 papers	19,318 citations	41323 49 h-index	11928 134 g-index
157 all docs	157 docs citations	157 times ranked	23930 citing authors

#	Article	IF	Citations
1	FGF7â€“FGFR2 autocrine signaling increases growth and chemoresistance of fusionâ€positive rhabdomyosarcomas. Molecular Oncology, 2022, 16, 1272-1289.	2.1	7
2	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. European Journal of Cancer, 2022, 172, 367-386.	1.3	19
3	Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer, 2021, 68, e28798.	0.8	38
4	Hypoxia and its therapeutic possibilities in paediatric cancers. British Journal of Cancer, 2021, 124, 539-551.	2.9	28
5	Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response. Cancer Research, 2021, 81, 1667-1680.	0.4	32
6	Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A. Cancers, 2021, 13, 1734.	1.7	6
7	Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) â€“ RMS2005 study. European Journal of Cancer, 2021, 151, 84-93.	1.3	21
8	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Journal of Clinical Oncology, 2021, 39, 2859-2871.	0.8	101
9	Experimental Models. Pediatric Oncology, 2021, , 129-147.	0.5	0
10	Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. Cancer Research, 2020, 80, 832-842.	0.4	31
11	Genomic landscape of platinum resistant and sensitive testicular cancers. Nature Communications, 2020, 11, 2189.	5.8	43
12	Desmoplastic small round cell tumor (DSRCT): emerging therapeutic targets and future directions for potential therapies. Expert Opinion on Therapeutic Targets, 2020, 24, 281-285.	1.5	11
13	Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1659-1670.	1.2	13
14	Epigenetic Targets in Synovial Sarcoma: A Mini-Review. Frontiers in Oncology, 2019, 9, 1078.	1.3	22
15	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European Journal of Cancer, 2019, 121, 224-235.	1.3	44
16	Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. Pediatric Blood and Cancer, 2019, 66, e27888.	0.8	19
17	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood and Cancer, 2019, 66, e27869.	0.8	57
18	Vgll3 operates via Tead1, Tead3 and Tead4 to influence myogenesis in skeletal muscle. Journal of Cell Science, 2019, 132, .	1.2	48

#	Article	IF	Citations
19	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas. Frontiers in Oncology, 2019, 9, 1271.	1.3	12
20	Rhabdomyosarcoma. Nature Reviews Disease Primers, 2019, 5, 1.	18.1	619
21	The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells. BMC Cancer, 2018, 18, 217.	1.1	25
22	IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. Journal of Pathology, 2018, 244, 242-253.	2.1	24
23	Fusion status in patients with lymph nodeâ€positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer, 2018, 124, 3201-3209.	2.0	51
24	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 19, 1061-1071.	5.1	137
25	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Scientific Reports, 2018, 8, 10614.	1.6	13
26	Targeted resequencing of pediatric rhabdomyosarcoma: report from the Childrenâ€™s Oncology Group, the Childrenâ€™s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.. Journal of Clinical Oncology, 2018, 36, 10515-10515.	0.8	9
27	Abstract 2975: Synthetic lethality in synovial sarcoma: SS18-SSX fusions and DNA damage response (DDR) inhibitors. , 2018, , .		0
28	Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nature Genetics, 2017, 49, 1133-1140.	9.4	120
29	Fusion gene addiction: can tumours be forced to give up the habit?. Journal of Pathology, 2017, 242, 263-266.	2.1	4
30	Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials. Pediatric Blood and Cancer, 2017, 64, e26386.	0.8	21
31	MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. Cancer Letters, 2017, 385, 251-260.	3.2	30
32	ATR Is a Therapeutic Target in Synovial Sarcoma. Cancer Research, 2017, 77, 7014-7026.	0.4	43
33	Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget, 2017, 8, 71371-71384.	0.8	85
34	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	0.8	16
35	Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. Clinical Cancer Research, 2016, 22, 1265-1273.	3.2	23
36	Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. British Journal of Cancer, 2016, 115, 473-479.	2.9	23

#	Article	IF	Citations
37	The Hippo effector <scp>TAZ</scp> (<scp>WWTR1</scp>) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma. Journal of Pathology, 2016, 240, 3-14.	2.1	40
38	Genome-wide methylation analysis identifies genes silenced in non-seminoma cell lines. Npj Genomic Medicine, 2016, 1, 15009.	1.7	6
39	The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. Nature Reviews Urology, 2016, 13, 409-419.	1.9	83
40	8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 1388-1409.	2.9	83
41	Molecular biomarkers of risk in rare and other cancers â€“ identification and impact. Biochemist, 2016, 38, 10-13.	0.2	0
42	Polygenic susceptibility to testicular cancer: implications for personalised health care. British Journal of Cancer, 2015, 113, 1512-1518.	2.9	10
43	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nature Communications, 2015, 6, 5973.	5.8	161
44	Identification of four new susceptibility loci for testicular germ cell tumour. Nature Communications, 2015, 6, 8690.	5.8	36
45	Less Can Be More for Gene Dose and Drug Sensitivity. Clinical Cancer Research, 2015, 21, 4750-4752.	3.2	0
46	Clinical Application of Prognostic Gene Expression Signature in Fusion Geneâ€“Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2015, 21, 4733-4739.	3.2	21
47	Abstract 2986: Meta-analysis of whole exome sequencing data reveals the mutational spectrum of testicular germ cell tumors. , 2015, , .		1
48	Ageâ€related biological features of germ cell tumors. Genes Chromosomes and Cancer, 2014, 53, 215-227.	1.5	24
49	Identification of ZDHHC14 as a novel human tumour suppressor gene. Journal of Pathology, 2014, 232, 566-577.	2.1	44
50	Rhabdomyosarcoma: Current Challenges and Their Implications for Developing Therapies. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a025650-a025650.	2.9	60
51	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. Cancer Cell, 2014, 26, 273-287.	7.7	152
52	Distinct Effects of Ligand-Induced PDGFRÎ± and PDGFRÎ² Signaling in the Human Rhabdomyosarcoma Tumor Cell and Stroma Cell Compartments. Cancer Research, 2013, 73, 2139-2149.	0.4	83
53	HES6 enhances the motility of alveolar rhabdomyosarcoma cells. Experimental Cell Research, 2013, 319, 103-112.	1.2	9
54	Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nature Genetics, 2013, 45, 686-689.	9.4	149

#	Article	IF	Citations
55	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo. Clinical Cancer Research, 2013, 19, 5940-5951.	3.2	124
56	Prediction of relapse in stage I nonseminomatous germ cell tumors (NSGCT) by CXCL12: Results from the MRC TE08 and TE22 clinical trials.. Journal of Clinical Oncology, 2013, 31, 319-319.	0.8	4
57	Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy. Clinical Cancer Research, 2012, 18, 796-807.	3.2	74
58	Inconvenience of Convenience Cohortsâ€"Letter. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1388-1388.	1.1	3
59	Reply to S. Stegmaier et al. Journal of Clinical Oncology, 2012, 30, 4040-4041.	0.8	4
60	Oncocytic Adrenal Cortical Carcinosarcoma With Pleomorphic Rhabdomyosarcomatous Metastases. American Journal of Surgical Pathology, 2012, 36, 470-477.	2.1	26
61	Immunohistochemical Detection of Glypican-5 in Paraffin-embedded Material. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 189-195.	0.6	2
62	Fluorescence In Situ Hybridization for Cancer-Related Studies. Methods in Molecular Biology, 2012, 878, 149-174.	0.4	7
63	PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. Journal of Clinical Oncology, 2012, 30, 1670-1677.	0.8	297
64	Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives. Sarcoma, 2011, 2011, 1-11.	0.7	45
65	Testicular germ cell tumours: predisposition genes and the male germ cell niche. Nature Reviews Cancer, 2011, 11, 278-288.	12.8	86
66	Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes Chromosomes and Cancer, 2011, 50, 186-195.	1.5	21
67	Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas. Journal of Clinical Pathology, 2011, 64, 587-591.	1.0	18
68	Abstract 5343: Aberrant activation of hedgehog signaling confers a poor prognosis in embryonal and fusion gene negative alveolar rhabdomyosarcoma. , 2011, , .		0
69	Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2. Cellular Signalling, 2010, 22, 357-365.	1.7	14
70	No evidence for V600E BRAF mutation in the seminoma cell line TCam-2. Genes Chromosomes and Cancer, 2010, 49, 963-966.	1.5	6
71	A census of amplified and overexpressed human cancer genes. Nature Reviews Cancer, 2010, 10, 59-64.	12.8	480
72	Reply to J.R. Anderson et al. Journal of Clinical Oncology, 2010, 28, e589-e590.	0.8	2

#	Article	IF	Citations
73	Fusion Geneâ€“Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma. Journal of Clinical Oncology, 2010, 28, 2151-2158.	0.8	426
74	Distinct roles for miRâ€1 and miRâ€133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB Journal, 2010, 24, 3427-3437.	0.2	118
75	The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers. American Journal of Pathology, 2010, 176, 2607-2615.	1.9	89
76	Fluorescence In Situ Hybridization Analysis of Formalin Fixed Paraffin Embedded Tissues, Including Tissue Microarrays. Methods in Molecular Biology, 2010, 659, 51-70.	0.4	13
77	Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development. Genes Chromosomes and Cancer, 2009, 48, 455-467.	1.5	98
78	Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. Journal of Pathology, 2009, 217, 94-102.	2.1	74
79	Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults. Genes Chromosomes and Cancer, 2008, 47, 547-557.	1.5	48
80	DYRK1A-Dosage Imbalance Perturbs NRSF/REST Levels, Deregulating Pluripotency and Embryonic Stem Cell Fate in Down Syndrome. American Journal of Human Genetics, 2008, 83, 388-400.	2.6	139
81	Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nature Protocols, 2008, 3, 220-234.	5.5	50
82	Subtle genomic alterations and genomic instability revealed in diploid cancer cell lines. Cancer Letters, 2008, 267, 49-54.	3.2	4
83	The pattern of genomic gains in salivary gland MALT lymphomas. Haematologica, 2007, 92, 921-927.	1.7	25
84	Clinical relevance of molecular genetics to paediatric sarcomas. Journal of Clinical Pathology, 2007, 60, 1187-1194.	1.0	52
85	Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma. Cancer Research, 2007, 67, 57-65.	0.4	94
86	An additional human chromosome 21 causes suppression of neural fate of pluripotent mouse embryonic stem cells in a teratoma model. BMC Developmental Biology, 2007, 7, 131.	2.1	17
87	The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors, 2006, 24, 197-208.	0.5	38
88	Testicular germ-cell cancer. Lancet, The, 2006, 367, 754-765.	6.3	370
89	Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer, 2006, 54, 155-162.	0.9	78
90	No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. Cancer Letters, 2006, 235, 136-140.	3.2	20

#	Article	IF	Citations
91	Comparative genomic hybridization and BUB1B mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome. Cancer Letters, 2006, 239, 234-238.	3.2	39
92	Putting the colours into chromogenicin situ hybridization (CISH). Journal of Pathology, 2006, 210, 1-2.	2.1	7
93	Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. Pediatric Blood and Cancer, 2006, 46, 820-824.	0.8	9
94	Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). British Journal of Haematology, 2006, 133, 35-42.	1.2	56
95	Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma. Genes Chromosomes and Cancer, 2006, 45, 839-845.	1.5	50
96	Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene. Cancer Research, 2006, 66, 290-302.	0.4	208
97	Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. Genes Chromosomes and Cancer, 2005, 43, 315-328.	1.5	14
98	Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines. Genes Chromosomes and Cancer, 2005, 43, 211-216.	1.5	22
99	Amplification and Overexpression of the KIT Gene Is Associated with Progression in the Seminoma Subtype of Testicular Germ Cell Tumors of Adolescents and Adults. Cancer Research, 2005, 65, 8085-8089.	0.4	149
100	Relationship Between MYCN Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype. Journal of Clinical Oncology, 2005, 23, 880-888.	0.8	106
101	Association between Large-scale Genomic Homozygosity without Chromosomal Loss and Nonseminomatous Germ Cell Tumor Development. Cancer Research, 2005, 65, 9137-9141.	0.4	14
102	Activating Mutations and/or Expression Levels of Tyrosine Kinase Receptors GRB7, RAS, and BRAF in Testicular Germ Cell Tumors. Neoplasia, 2005, 7, 1047-1052.	2.3	70
103	A Gene Expression Signature Associated with Metastatic Outcome in Human Leiomyosarcomas. Cancer Research, 2004, 64, 7201-7204.	0.4	73
104	Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene, 2004, 23, 9142-9147.	2.6	38
105	Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp andSTK11-negative PJS cases. Genes Chromosomes and Cancer, 2004, 41, 163-169.	1.5	29
106	Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. Cancer Genetics and Cytogenetics, 2003, 140, 73-77.	1.0	35
107	Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior. Genes Chromosomes and Cancer, 2003, 38, 207-214.	1.5	18
108	Role of gain of 12p in germ cell tumour development. Apmis, 2003, 111, 161-173.	0.9	126

#	Article	IF	Citations
109	Loss of 13q14-q21 and Gain of 5p14-pter in the Progression of Leiomyosarcoma. Modern Pathology, 2003, 16, 778-785.	2.9	27
110	Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet, The, 2002, 360, 385-386.	6.3	57
111	Mediastinal synovial sarcoma: report of two cases with molecular genetic analysis. Annals of Thoracic Surgery, 2002, 73, 628-630.	0.7	39
112	Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes and Cancer, 2002, 34, 104-114.	1.5	66
113	Unusual case of leukemic mantle cell lymphoma with amplifiedCCND1/IGH fusion gene. Genes Chromosomes and Cancer, 2002, 33, 206-212.	1.5	31
114	The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. Oncogene, 2002, 21, 5791-5796.	2.6	42
115	Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.	13.7	9,374
116	Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Research, 2002, 62, 135-40.	0.4	390
117	Gain of 1q Is Associated with Adverse Outcome in Favorable Histology Wilmsâ€™ Tumors. American Journal of Pathology, 2001, 158, 393-398.	1.9	127
118	Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis. Genes Chromosomes and Cancer, 2001, 31, 54-64.	1.5	55
119	Disruption of the ATM gene in breast cancer. Cancer Genetics and Cytogenetics, 2001, 126, 97-101.	1.0	14
120	Definition of chromosome aberrations in testicular germ cell tumor cell lines by 24-color karyotyping and complementary molecular cytogenetic analyses. Cancer Genetics and Cytogenetics, 2001, 128, 120-129.	1.0	25
121	Characterization of chromosome 1 abnormalities in malignant melanomas. , 2000, 28, 121-125.		69
122	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. , 2000, 28, 220-226.		75
123	Evaluation of 24-color multifluor-fluorescence in-situ hybridization (M-FISH) karyotyping by comparison with reverse chromosome painting of the human breast cancer cell line T-47D. Chromosome Research, 2000, 8, 127-132.	1.0	18
124	Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes and Cancer, 1999, 26, 275-285.	1.5	145
125	Synovial sarcoma specific translocation associated with both epithelial and spindle cell components. , 1999, 82, 605-608.		32
126	Dual colour fluorescencein situ hybridization to paraffin-embedded samples to deduce the presence of the der(X)t(X;18)(p11.2;q11.2) and involvement of either theSSX1 orSSX2 gene: a diagnostic and prognostic aid for synovial sarcoma. , 1999, 187, 490-496.		55

#	Article	IF	Citations
127	Chromosome 3 imbalances are the most frequent aberration found in non-small cell lung carcinoma. Lung Cancer, 1999, 23, 61-66.	0.9	30
128	Cloning and Mapping of Members of the MYM Family. Genomics, 1999, 60, 244-247.	1.3	28
129	Poorly Differentiated Synovial Sarcoma. American Journal of Surgical Pathology, 1999, 23, 106-112.	2.1	209
130	Chromosome translocations in sarcomas and the analysis of paraffin-embedded material. , 1998, 184, 1-3.		9
131	Characterization of a t(8;13)(p11;q11-12) in an atypical myeloproliferative disorder. Genes Chromosomes and Cancer, 1998, 21, 70-73.	1.5	14
132	cDNA Cloning of a Third Human C2-Domain-Containing Class II Phosphoinositide 3-Kinase, PI3K-C2Î³, and Chromosomal Assignment of This Gene (PIK3C2G) to 12p12. Genomics, 1998, 54, 569-574.	1.3	57
133	Establishing Germ Cell Origin of Undifferentiated Tumors by Identifying Gain of 12p Material Using Comparative Genomic Hybridization Analysis of Paraffin-Embedded Samples. Diagnostic Molecular Pathology, 1998, 7, 260-266.	2.1	39
134	Identification and cDNA Cloning of a Novel Mammalian C2 Domain-Containing Phosphoinositide 3-Kinase, HsC2-PI3K. Biochemical and Biophysical Research Communications, 1997, 233, 537-544.	1.0	64
135	Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk. Oncogene, 1997, 15, 1497-1502.	2.6	44
136	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 1997, 15, 2233-2239.	2.6	298
137	Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence. Genes Chromosomes and Cancer, 1997, 20, 275-281.	1.5	59
138	Primitive Neuroectodermal Tumor of the Kidney Confirmed by Fluorescence In Situ Hybridization. American Journal of Surgical Pathology, 1997, 21, 461-468.	2.1	56
139	Characterisation of a human serine hydroxymethyltransferase pseudogene and its localisation to 1p32.3â€“33. Human Genetics, 1996, 97, 340-344.	1.8	10
140	REVIEW ARTICLE. THE MOLECULAR PATHOLOGY OF SMALL ROUND-CELL TUMOURSâ€”RELEVANCE TO DIAGNOSIS, PROGNOSIS, AND CLASSIFICATION. , 1996, 178, 116-121.		68
141	INTERPHASE FLUORESCENCEIN SITU HYBRIDIZATION DETECTION OF t(2;13)(q35;q14) IN ALVEOLAR RHABDOMYOSARCOMAâ€”A DIAGNOSTIC TOOL IN MINIMALLY INVASIVE BIOPSIES. , 1996, 178, 410-414.		44
142	Loss of the chromosomal region 5q11-q31 in the myeloid cell line HL-60: Characterization by comparative genomic hybridization and fluorescence in situ hybridization. , 1996, 15, 182-186.		14
143	Novel formation and amplification of thePAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. , 1996, 17, 7-13.		50
144	Recent advances in the diagnosis, prognosis and classification of childhood solid tumours. British Medical Bulletin, 1996, 52, 724-741.	2.7	7

#	Article	IF	Citations
145	INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION DETECTION OF t(2;13)(q35;q14) IN ALVEOLAR RHABDOMYOSARCOMAâ€"A DIAGNOSTIC TOOL IN MINIMALLY INVASIVE BIOPSIES. Journal of Pathology, 1996, 178, 410-414.	2.1	2
146	Characterisation of a human serine hydroxymethyltransferase pseudogene and its localisation to 1p32.3-33. Human Genetics, 1996, 97, 340-344.	1.8	0
147	Characterization of a t(10; 11) (p13-14; q14-21) in the monoblastic cell line U937. Genes Chromosomes and Cancer, 1995, 13, 138-142.	1.5	8
148	Diagnosis of Ewing's sarcoma and related tumours by detection of chromosome 22q12 translocations using fluorescencein situ hybridization on tumour touch imprints. Journal of Pathology, 1995, 176, 137-142.	2.1	40
149	Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genetics, 1994, 7, 502-508.	9.4	723
150	The molecular biology of soft tissue sarcomas. European Journal of Cancer, 1993, 29, 2054-2058.	1.3	12